Marilyn C. Pike

3.9k total citations · 2 hit papers
36 papers, 2.8k citations indexed

About

Marilyn C. Pike is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Marilyn C. Pike has authored 36 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Immunology, 11 papers in Molecular Biology and 8 papers in Oncology. Recurrent topics in Marilyn C. Pike's work include Immune cells in cancer (9 papers), Systemic Lupus Erythematosus Research (5 papers) and Cytokine Signaling Pathways and Interactions (5 papers). Marilyn C. Pike is often cited by papers focused on Immune cells in cancer (9 papers), Systemic Lupus Erythematosus Research (5 papers) and Cytokine Signaling Pathways and Interactions (5 papers). Marilyn C. Pike collaborates with scholars based in United States, Australia and Germany. Marilyn C. Pike's co-authors include Ralph Snyderman, Roger J. Laham, Michael Simons, James E. Udelson, M.J. Whitehouse, Nicolas A.F. Chronos, Brian H. Annex, Timothy D. Henry, Thomas E. Moon and Harold L. Dauerman and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Marilyn C. Pike

36 papers receiving 2.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2

2002 512 citations Michael Simons, Brian H. Annex et al. Circulation profile →
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

2022 139 citations Eric F. Morand, Marilyn C. Pike et al. Arthritis & Rheumatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marilyn C. Pike United States	25	1.1k	890	592	525	514	36	2.8k
Linda K. Myers United States	31	651 0.6×	1.4k 1.6×	648 1.1×	816 1.6×	430 0.8×	102	3.2k
Anwen S. Williams United Kingdom	35	913 0.8×	1.8k 2.0×	828 1.4×	336 0.6×	1.1k 2.1×	86	4.0k
J. Davignon France	26	669 0.6×	995 1.1×	475 0.8×	216 0.4×	238 0.5×	88	2.4k
J. Philip McCoy United States	35	2.1k 1.9×	796 0.9×	143 0.2×	194 0.4×	830 1.6×	99	4.4k
John Ransom United States	31	1.3k 1.1×	1.3k 1.5×	157 0.3×	307 0.6×	481 0.9×	58	3.1k
M Ziff United States	34	792 0.7×	1.9k 2.2×	1.0k 1.7×	874 1.7×	367 0.7×	103	4.4k
Frédérique Ponchel United Kingdom	36	1.1k 0.9×	1.6k 1.8×	1.4k 2.4×	504 1.0×	728 1.4×	108	4.3k
Chul‐Soo Cho South Korea	29	750 0.7×	675 0.8×	848 1.4×	177 0.3×	347 0.7×	73	2.4k
Ingo H. Tarner Germany	24	945 0.8×	936 1.1×	1.1k 1.9×	226 0.4×	592 1.2×	84	3.1k
R Pigott United Kingdom	20	1.1k 0.9×	929 1.0×	139 0.2×	217 0.4×	437 0.9×	28	3.0k

Countries citing papers authored by Marilyn C. Pike

Since Specialization

Citations

This map shows the geographic impact of Marilyn C. Pike's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marilyn C. Pike with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marilyn C. Pike more than expected).

Fields of papers citing papers by Marilyn C. Pike

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marilyn C. Pike. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marilyn C. Pike. The network helps show where Marilyn C. Pike may publish in the future.

Co-authorship network of co-authors of Marilyn C. Pike

This figure shows the co-authorship network connecting the top 25 collaborators of Marilyn C. Pike. A scholar is included among the top collaborators of Marilyn C. Pike based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marilyn C. Pike. Marilyn C. Pike is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Morand, Eric F., Marilyn C. Pike, Joan T. Merrill, et al.. (2024). Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus. Expert Opinion on Investigational Drugs. 33(5). 431–440. 2 indexed citations

Werth, Victoria P., Marilyn C. Pike, Joan T. Merrill, et al.. (2023). Efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: Results from a phase 2, randomized, double-blind, placebo-controlled study. SKIN The Journal of Cutaneous Medicine. 7(2). s114–s114. 1 indexed citations

Morand, Eric F., Marilyn C. Pike, Joan T. Merrill, et al.. (2022). Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial. Arthritis & Rheumatology. 75(2). 242–252. 139 indexed citations breakdown →

Clowse, Megan E. B., Daniel J. Wallace, Richard Furie, et al.. (2016). Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials. Arthritis & Rheumatology. 69(2). 362–375. 169 indexed citations

Wallace, Daniel J., Kenneth Kalunian, Michelle Petri, et al.. (2013). Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Annals of the Rheumatic Diseases. 73(1). 183–190. 250 indexed citations

Pike, Marilyn C., et al.. (2012). Data Quality Challenges in Systemic Lupus Erythematosus Trials: How Can This Be Optimized?. Current Rheumatology Reports. 14(4). 324–333. 11 indexed citations

Hunter, David J., Marilyn C. Pike, Beth Jonas, et al.. (2010). Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis. BMC Musculoskeletal Disorders. 11(1). 232–232. 118 indexed citations

Simons, Michael, Brian H. Annex, Roger J. Laham, et al.. (2002). Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2. Circulation. 105(7). 788–793. 512 indexed citations breakdown →

Bush, Mark, Emil Samara, M.J. Whitehouse, et al.. (2001). Pharmacokinetics and Pharmacodynamics of Recombinant FGF‐2 in a Phase I Trial in Coronary Artery Disease. The Journal of Clinical Pharmacology. 41(4). 378–385. 40 indexed citations

10.

Laham, Roger J., Marilyn C. Pike, James E. Udelson, et al.. (2000). Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a Phase I open-label dose escalation study. Journal of the American College of Cardiology. 36(7). 2132–2139. 170 indexed citations

11.

Nemunaitis, John, Timothy Fong, Joan M. Robbins, et al.. (1999). Phase I trial of interferon-γ (IFN-γ) retroviral vector administered intratumorally to patients with metastatic melanoma. Cancer Gene Therapy. 6(4). 322–330. 39 indexed citations

12.

Pike, Marilyn C., et al.. (1993). Characterization of interleukin-8 receptors in human neutrophil membranes: Regulation by guanine nucleotides. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1177(3). 275–282. 15 indexed citations

13.

Babich, John W., Howard F. Solomon, Marilyn C. Pike, et al.. (1993). Technetium-99m-labeled hydrazino nicotinamide derivatized chemotactic peptide analogs for imaging focal sites of bacterial infection.. PubMed. 34(11). 1964–74. 81 indexed citations

14.

Sager, Ruth, Stephen Haskill, Anthony Anisowicz, Douglas K. Trask, & Marilyn C. Pike. (1991). GRO: A Novel Chemotactic Cytokine. Advances in experimental medicine and biology. 305. 73–77. 20 indexed citations

15.

Pike, Marilyn C., et al.. (1989). Increased Phosphatidylinositol Kinase Activity in Psoriatic Epidermis. Journal of Investigative Dermatology. 92(6). 791–797. 17 indexed citations

16.

Pike, Marilyn C. & Ralph Snyderman. (1985). Regulation of Mononuclear Leukocyte Function by Transmethylation Reactionsa. Annals of the New York Academy of Sciences. 451(1). 256–263. 1 indexed citations

17.

Snyderman, Ralph & Marilyn C. Pike. (1984). Transductional Mechanisms of Chemoattractant Receptors on Leukocytes. PubMed. 14. 1–28. 38 indexed citations

18.

Pike, Marilyn C. & Ralph Snyderman. (1982). Transmethylation reactions regulate affinity and functional activity of chemotactic factor receptors on macrophages. Cell. 28(1). 107–114. 45 indexed citations

19.

Snyderman, Ralph & Marilyn C. Pike. (1980). N -Formylmethionyl Peptide Receptors on Equine Leukocytes Initiate Secretion But Not Chemotaxis. Science. 209(4455). 493–495. 56 indexed citations

20.

Snyderman, Ralph, Marilyn C. Pike, Dina G. Fischer, & Hillel S. Koren. (1977). Biologic and Biochemical Activities of Continuous Macrophage Cell Lines P388D1 and J774.1. The Journal of Immunology. 119(6). 2060–2066. 117 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact